AgeX Therapeutics Book Value 2011-2026 | AGE

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value AgeX Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
5.36 M	-17.3 M	-11.9 M	-5.4 M	2.62 M	8.23 M	8.32 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
8.32 M	-17.3 M	-1.44 M

Quarterly Book Value AgeX Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
1.59 M	1.65 M	1.56 M	508 K	-13.8 M	-16.4 M	-4.31 M	4.11 M	8.31 M	-22.3 M	-20 M	-17.3 M	-15.1 M	-13.3 M	-11.6 M	-11.9 M	-9.98 M	-8.29 M	-6.1 M	-5.4 M	-5.4 M	-5.4 M	-5.4 M	2.62 M	2.62 M	2.62 M	2.62 M	8.23 M	8.23 M	8.23 M	8.23 M	8.32 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
8.32 M	-22.3 M	-3.83 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	11.8 M	$ 0.82	-3.48 %	$ 4.47 M	China
Rigel Pharmaceuticals RIGL	391 M	$ 33.23	-4.03 %	$ 584 M	USA
Graybug Vision GRAY	-6.64 M	-	-11.23 %	$ 9.65 M	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Apellis Pharmaceuticals APLS	370 M	$ 20.15	-2.68 %	$ 2.54 B	USA
AbCellera Biologics ABCL	967 M	$ 3.72	-2.75 %	$ 1.11 B	Canada
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
AVEO Pharmaceuticals AVEO	45.9 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	88.3 M	$ 163.7	-1.61 %	$ 8.14 B	USA
BridgeBio Pharma BBIO	-2.08 B	$ 64.66	-1.37 %	$ 12.4 B	USA
Brainstorm Cell Therapeutics BCLI	-7.76 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	188 M	-	-4.8 %	$ 255 M	USA
Burford Capital Limited BUR	1.66 B	$ 8.52	-2.46 %	$ 1.39 B	Britain
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
CymaBay Therapeutics CBAY	292 M	-	-	$ 3.45 B	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Avid Bioservices CDMO	60.9 M	-	-	$ 789 M	USA
Certara CERT	1.06 B	$ 7.16	1.49 %	$ 1.15 B	USA
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Checkpoint Therapeutics CKPT	-12.6 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	29.3 M	-	-16.75 %	$ 25.8 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Clovis Oncology CLVS	-279 M	-	-7.23 %	$ 13 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Checkmate Pharmaceuticals CMPI	69.5 M	-	-	$ 231 M	USA
Capricor Therapeutics CAPR	22.6 M	$ 25.91	-3.56 %	$ 694 M	USA
Catalyst Pharmaceuticals CPRX	954 M	$ 24.0	0.5 %	$ 2.93 B	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Codexis CDXS	66.9 M	$ 0.99	-3.28 %	$ 72.7 M	USA
Corvus Pharmaceuticals CRVS	38.7 M	$ 17.75	-0.79 %	$ 852 M	USA
CTI BioPharma Corp. CTIC	-17.6 M	-	-	$ 1.2 B	USA
CohBar CWBR	15.3 M	-	-15.44 %	$ 2.2 M	USA
Cyclacel Pharmaceuticals CYCC	-2.17 M	-	-5.98 %	$ 34.1 M	USA
Cyclacel Pharmaceuticals CYCCP	-2.17 M	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	351 M	-	-	$ 2.18 B	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Denali Therapeutics DNLI	1.23 B	$ 20.02	-4.67 %	$ 3.29 B	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Eton Pharmaceuticals ETON	15.5 M	$ 17.54	-3.36 %	$ 450 M	USA
Entasis Therapeutics Holdings ETTX	31.2 M	-	-	$ 105 M	USA
Evofem Biosciences EVFM	-61.9 M	-	7.55 %	$ 38.1 M	USA